Navigation Links
Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
Date:8/3/2009

WALTHAM, Mass., Aug. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2013 to 2018, generic erosion of established agents--most notably tamsulosin--will cause a decline of more than eight percent in the drug market for benign prostatic hyperplasia and male lower urinary tract symptoms in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Generic erosion will offset market growth of more than seven percent that will be driven by the uptake of emerging agents from 2008 to 2013.

The new Pharmacor report entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms finds that the market is saturated with effective, well-established agents. The market is also concentrated as, in 2008, tamsulosin garnered just over half of all major-market sales for benign prostatic hyperplasia. Tamsulosin, the most widely-used alpha blocker for the indication, is marketed by Boehringer Ingelheim as Flomax/Josir/Alna/Pradif/Urolosin and by Astellas as Omix/Omnic/Flomaxtra/Harnal. Generic versions of tamsulosin have been available in Europe and Japan since 2006 and, in the first half of 2010, the drug will be generically available in the United States as well. As a result of generic competition, tamsulosin's annual major-market sales will plummet 41 percent between 2008 and 2013, according to the report.

The report also finds that, while symptom relief remains the primary concern in treating the disease, drug development for benign prostatic hyperplasia has focused on improving dosing convenience and slowing disease progression. Owing to its dosing convenience, GlaxoSmithKline's tamsulosin/dutasteride fixed-dose combination Duodart will likely increase compliance, while Aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and Aeterna Zentaris/Spectrum Pharmaceuticals/Nippon Kayaku's ozarelix both aim to reduce the size of the prostate and slow disease progression. Additionally, the report finds that drug developers are also focusing on targeting comorbidities, such as erectile dysfunction, with a single agent, namely, Eli Lilly's Cialis.

"If it's approved for the indication, Cialis will be used to treat patients diagnosed with both male lower urinary tract symptoms and erectile dysfunction," said Decision Resources Analyst Benjamin Guikema, Ph.D. "Although we anticipate that, if approved, Cialis would face substantial reimbursement hurdles for the disease through 2018, it has the potential to establish itself as a dominant therapy in the benign prostatic hyperplasia and male lower urinary tract symptoms market if it were to obtain favorable reimbursement in the years after that."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563
    ccomfort@dresources.com    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Generic prostate drug helps find high-risk cancers early
7. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
9. FDA Announces Initiative to Bolster Generic Drug Program
10. FDA Struggles to Keep Pace With Requests for Generics
11. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is not ... communities have begun providing weekend displays, and numerous households celebrate the unofficial end of ... be downright terrifying for pets. , Kris Zambo, owner of Dynamite Fireworks ...
(Date:8/21/2017)... , ... August 22, 2017 , ... ... not without risk to health and safety. By learning and implementing best practices ... , In this webinar, attendees will gain a better understanding of a ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area medical ... for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This ... Plastic and Reconstructive Surgery. The candidate will have the opportunity to work ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... it has become the Official Technology Partner of North Country Region Volleyball and ... Event Systems) volleyball software, along with providing sport management software to their member ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has ... the country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that ... of melanoma, and only half may be adequately protecting themselves with proper clothing ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County ... its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The ... disinfection robot that uses UVC light energy to kill deadly pathogens such as C. ... Tru-D SmartUVC ... Tru-D in action in ...
Breaking Medicine Technology: